Explore licensed vaccines, adverse event reporting data, and history for this disease.
- Phase 1
- Phase 2
- Phase 3
- Filed
- Approved
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Under Regulatory Review Date: 2024-10-15BLA submitted to FDA following positive Phase 3 immunogenicity data vs separate flu & COVID vaccines |
| EMA (Europe) | Under Regulatory Review Date: 2024-11-01EMA regulatory submission planned/under review |
| Health Canada | Not Filed / Pre-submission Date: 2025-02-01Filing anticipated |
| TGA (Australia) | Not Filed / Pre-submission Date: 2025-03-01Filing anticipated |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Current position: Submitted to a regulator
| Jurisdiction | Status in the record | Submission | Regulator decision | Earliest routine use |
|---|---|---|---|---|
| United StatesFDA (CBER) · ACIP (CDC) | under review (2024-10-15, regulator confirmed) | 2024-102024-10 to 2024-10 | 2027-012026-11 to 2027-07 | 2027-042026-11 to 2028-03 |
| European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others) | under review (2024-11-01, company estimate) | 2024-112024-11 to 2024-11 | 2027-012026-11 to 2027-07 | 2027-072026-12 to 2029-01 |
| CanadaHealth Canada · NACI | not filed (2025-02-01, company estimate) | 2026-102026-10 to 2026-10 | 2027-082027-04 to 2028-01 | 2027-122027-05 to 2029-01 |
| United KingdomMHRA · JCVI | no jurisdiction-specific filing known | The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used. | ||
| AustraliaTGA · ATAGI | not filed (2025-03-01, company estimate) | TGA registration-timeframe pages timed out on 2026-10-24; no target is used. | ||
| JapanPMDA / MHLW · MHLW immunisation subcommittee | no jurisdiction-specific filing known | PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure. | ||
| WHO prequalificationWHO Prequalification · SAGE | no jurisdiction-specific filing known | WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used. | ||
Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.
Scientific Profile & Documentation
- Platform Architecture
- mRNA
- Lead Developer
- Moderna
- Next Expected Milestone
- FDA target PDUFA action date and ACIP review for 2025-2026 respiratory season
- Analyst & Development Notes
- Illustrates multi-jurisdiction status: filed/under review in some regions while US pathway was withdrawn pending refiling.
- Primary Source Documentation
- Moderna Analyst Day / pipeline disclosures →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.
Milestone Overview
-
Stage VerificationRegulatory Submission Filed confirmed as of 2026-08-01.
-
Target MilestoneFDA target PDUFA action date and ACIP review for 2025-2026 respiratory season
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.